A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy

Paolo Ragonese, Giovanni Frisullo, Valentina Tomassini, Damiano Paolicelli, Simona Malucchi, Luca Roccatagliata, Marco Vercellino, Laura Boffa, Eleonora Cocco, Claudio Solaro, Claudio Gasperini, Carla Tortorella, Massimiliano Calabrese, Ilaria Pesci, Mariaemma Rodegher, Cinzia Cordioli, Benedetta Bodini, Marta Radaelli, Giovanna De Luca, Pietro Annovazzi & 2 others Antonio Gallo, Valentina Zipoli

Risultato della ricerca: Article

Abstract

Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage (%) of 21 relapses resulting in a prescription was 88.9%. Corticosteroids represented the most frequent prescription. A short-course of high-dose intravenous methylprednisolone was the most used corticosteroid (73.7%). Treatment was administrated mainly in day case unit (80.0%) and at home (13.6%). A tapered therapy was prescribed to 28.8% of patients. Neurologists' therapeutic decisions were driven mainly by relapse severity (45.3%) and symptom evolution (24.2%). Our study confirms the therapeutic attitude of multiple sclerosis specialists in treating relapses with high-dose intravenous corticosteroids in a day hospital setting, with a tapering in a proportion of cases. The main reasons for prescription are relapse severity and symptom evolution.
Lingua originaleEnglish
pagine (da-a)197-203
Numero di pagine7
RivistaNeurological Sciences
Volume34
Stato di pubblicazionePublished - 2013

Fingerprint

Italy
Multicenter Studies
Multiple Sclerosis
Cross-Sectional Studies
Recurrence
Prescriptions
Adrenal Cortex Hormones
Therapeutics
Methylprednisolone
Guidelines
Neurologists
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Dermatology
  • Psychiatry and Mental health
  • Clinical Neurology

Cita questo

Ragonese, P., Frisullo, G., Tomassini, V., Paolicelli, D., Malucchi, S., Roccatagliata, L., ... Zipoli, V. (2013). A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurological Sciences, 34, 197-203.

A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. / Ragonese, Paolo; Frisullo, Giovanni; Tomassini, Valentina; Paolicelli, Damiano; Malucchi, Simona; Roccatagliata, Luca; Vercellino, Marco; Boffa, Laura; Cocco, Eleonora; Solaro, Claudio; Gasperini, Claudio; Tortorella, Carla; Calabrese, Massimiliano; Pesci, Ilaria; Rodegher, Mariaemma; Cordioli, Cinzia; Bodini, Benedetta; Radaelli, Marta; De Luca, Giovanna; Annovazzi, Pietro; Gallo, Antonio; Zipoli, Valentina.

In: Neurological Sciences, Vol. 34, 2013, pag. 197-203.

Risultato della ricerca: Article

Ragonese, P, Frisullo, G, Tomassini, V, Paolicelli, D, Malucchi, S, Roccatagliata, L, Vercellino, M, Boffa, L, Cocco, E, Solaro, C, Gasperini, C, Tortorella, C, Calabrese, M, Pesci, I, Rodegher, M, Cordioli, C, Bodini, B, Radaelli, M, De Luca, G, Annovazzi, P, Gallo, A & Zipoli, V 2013, 'A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy', Neurological Sciences, vol. 34, pagg. 197-203.
Ragonese P, Frisullo G, Tomassini V, Paolicelli D, Malucchi S, Roccatagliata L e altri. A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurological Sciences. 2013;34:197-203.
Ragonese, Paolo ; Frisullo, Giovanni ; Tomassini, Valentina ; Paolicelli, Damiano ; Malucchi, Simona ; Roccatagliata, Luca ; Vercellino, Marco ; Boffa, Laura ; Cocco, Eleonora ; Solaro, Claudio ; Gasperini, Claudio ; Tortorella, Carla ; Calabrese, Massimiliano ; Pesci, Ilaria ; Rodegher, Mariaemma ; Cordioli, Cinzia ; Bodini, Benedetta ; Radaelli, Marta ; De Luca, Giovanna ; Annovazzi, Pietro ; Gallo, Antonio ; Zipoli, Valentina. / A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. In: Neurological Sciences. 2013 ; Vol. 34. pagg. 197-203.
@article{84a4e888a6274ed28e61ab7228e8e659,
title = "A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy",
abstract = "Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage ({\%}) of 21 relapses resulting in a prescription was 88.9{\%}. Corticosteroids represented the most frequent prescription. A short-course of high-dose intravenous methylprednisolone was the most used corticosteroid (73.7{\%}). Treatment was administrated mainly in day case unit (80.0{\%}) and at home (13.6{\%}). A tapered therapy was prescribed to 28.8{\%} of patients. Neurologists' therapeutic decisions were driven mainly by relapse severity (45.3{\%}) and symptom evolution (24.2{\%}). Our study confirms the therapeutic attitude of multiple sclerosis specialists in treating relapses with high-dose intravenous corticosteroids in a day hospital setting, with a tapering in a proportion of cases. The main reasons for prescription are relapse severity and symptom evolution.",
author = "Paolo Ragonese and Giovanni Frisullo and Valentina Tomassini and Damiano Paolicelli and Simona Malucchi and Luca Roccatagliata and Marco Vercellino and Laura Boffa and Eleonora Cocco and Claudio Solaro and Claudio Gasperini and Carla Tortorella and Massimiliano Calabrese and Ilaria Pesci and Mariaemma Rodegher and Cinzia Cordioli and Benedetta Bodini and Marta Radaelli and {De Luca}, Giovanna and Pietro Annovazzi and Antonio Gallo and Valentina Zipoli",
year = "2013",
language = "English",
volume = "34",
pages = "197--203",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy

AU - Ragonese, Paolo

AU - Frisullo, Giovanni

AU - Tomassini, Valentina

AU - Paolicelli, Damiano

AU - Malucchi, Simona

AU - Roccatagliata, Luca

AU - Vercellino, Marco

AU - Boffa, Laura

AU - Cocco, Eleonora

AU - Solaro, Claudio

AU - Gasperini, Claudio

AU - Tortorella, Carla

AU - Calabrese, Massimiliano

AU - Pesci, Ilaria

AU - Rodegher, Mariaemma

AU - Cordioli, Cinzia

AU - Bodini, Benedetta

AU - Radaelli, Marta

AU - De Luca, Giovanna

AU - Annovazzi, Pietro

AU - Gallo, Antonio

AU - Zipoli, Valentina

PY - 2013

Y1 - 2013

N2 - Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage (%) of 21 relapses resulting in a prescription was 88.9%. Corticosteroids represented the most frequent prescription. A short-course of high-dose intravenous methylprednisolone was the most used corticosteroid (73.7%). Treatment was administrated mainly in day case unit (80.0%) and at home (13.6%). A tapered therapy was prescribed to 28.8% of patients. Neurologists' therapeutic decisions were driven mainly by relapse severity (45.3%) and symptom evolution (24.2%). Our study confirms the therapeutic attitude of multiple sclerosis specialists in treating relapses with high-dose intravenous corticosteroids in a day hospital setting, with a tapering in a proportion of cases. The main reasons for prescription are relapse severity and symptom evolution.

AB - Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage (%) of 21 relapses resulting in a prescription was 88.9%. Corticosteroids represented the most frequent prescription. A short-course of high-dose intravenous methylprednisolone was the most used corticosteroid (73.7%). Treatment was administrated mainly in day case unit (80.0%) and at home (13.6%). A tapered therapy was prescribed to 28.8% of patients. Neurologists' therapeutic decisions were driven mainly by relapse severity (45.3%) and symptom evolution (24.2%). Our study confirms the therapeutic attitude of multiple sclerosis specialists in treating relapses with high-dose intravenous corticosteroids in a day hospital setting, with a tapering in a proportion of cases. The main reasons for prescription are relapse severity and symptom evolution.

UR - http://hdl.handle.net/10447/99662

M3 - Article

VL - 34

SP - 197

EP - 203

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -